AVXL

ANAVEX LIFE SCIENCES CORP.

AVXL · CIK 1314052 · Annual (10-K) · Last 8 years

Financial Trends

Revenue
20182025
Net Income−$46M
20182025
Operating CF−$39M
20182025
Free Cash Flow
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue————————
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense$0.0B———————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B————
Net Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-0.54$-0.52$-0.60—————
EPS (Diluted)$-0.54$-0.52$-0.60—————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.1B$0.1B$0.2B$0.2B$0.2B$0.0B$0.0B$0.0B
Current Assets——————$0.0B$0.0B
Cash & Equivalents$0.1B$0.1B$0.2B$0.1B$0.2B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B——
Current Liabilities——————$0.0B$0.0B
Stockholders' Equity$0.1B$0.1B$0.1B$0.1B$0.2B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow————————
Capital Expenditures————————
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.2B$0.0B$0.0B$0.0B
← Companies